Joseph O Merrill
Overview
Explore the profile of Joseph O Merrill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fortney J, Ratzliff A, Blanchard B, Johnson M, Ferro L, Austin E, et al.
Ann Intern Med
. 2023 Oct;
176(10):1431-1433.
PMID: 37844317
No abstract available.
12.
Tsui J, Stephens D, Collins B, Denisiuk E, Hallgren K, Blalock K, et al.
J Addict Med
. 2023 Aug;
17(4):491-492.
PMID: 37579119
No abstract available.
13.
Austin E, Chen J, Briggs E, Ferro L, Barry P, Heald A, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2328627.
PMID: 37566414
Importance: Medication for opioid use disorder (MOUD) (eg, buprenorphine and naltrexone) can be offered in primary care, but barriers to implementation exist. Objective: To evaluate an implementation intervention over 2...
14.
Vutien P, Kim N, Merrill J, Duncan M, Ioannou G, Collins S
J Addict Med
. 2023 Jun;
17(3):363-366.
PMID: 37267194
Objectives: The use of extended-release naltrexone (XR-NTX) as treatment for alcohol use disorder (AUD) has been limited by a prior black box warning for hepatotoxicity. We performed a secondary analysis...
15.
Jack H, Denisiuk E, Collins B, Stephens D, Blalock K, Klein J, et al.
Subst Abus
. 2022 Jul;
43(1):1308-1316.
PMID: 35896006
: People with opioid use disorder (OUD) are increasingly started on buprenorphine in the hospital, yet many patients do not attend outpatient buprenorphine care after discharge. Peer providers, people in...
16.
Bhatraju E, Klein J, Hall A, Chen D, Iles-Shih M, Tsui J, et al.
J Addict Med
. 2021 Dec;
16(4):461-465.
PMID: 34954743
Objective: To describe the outcomes of buprenorphine/naloxone low dose induction with overlap of full opioid agonists among hospitalized patients with opioid use disorder (OUD) as an alternative to standard induction...
17.
Tsui J, Leroux B, Radick A, Schramm Z, Blalock K, LaBelle C, et al.
Drug Alcohol Depend
. 2021 Aug;
227:108917.
PMID: 34399136
Background: We conducted a pilot study to assess feasibility of using video directly-observed therapy (DOT) for patients initiating buprenorphine to evaluate whether it is associated with better opioid use disorder...
18.
James J, Marolf M, Klein J, Blalock K, Merrill J, Tsui J
Subst Use Misuse
. 2021 Jul;
56(11):1569-1575.
PMID: 34282999
Purpose: Improving access to buprenorphine treatment is necessary to address the national opioid use disorder (OUD) crisis. This study investigates attitudes about buprenorphine prescribing among staff at a primary care...
19.
Chen J, Cabudol M, Williams E, Merrill J, Tsui J, Klein J
J Subst Abuse Treat
. 2021 Jun;
126:108463.
PMID: 34116814
Objectives: Office-based opioid treatment (OBOT) with buprenorphine is increasingly integrated in primary care to treat opioid use disorder (OUD). Online portals seek to engage patients in care of their chronic...
20.
Banta-Green C, Hansen R, Ossiander E, Wasserman C, Merrill J
J Subst Abuse Treat
. 2021 May;
127:108446.
PMID: 34049724
Background: Opioid use disorder is a serious health condition for which buprenorphine is proven effective, yet providers substantially underutilize buprenorphine. We present two approaches to measuring treatment duration, factors associated...